Adults aged 60 and over in the US will be eligible for vaccinations with respiratory syncytial virus (RSV) vaccines from GSK or Pfizer later this year, if the Centers for
Johnson & Johnson's also-ran COVID-19 vaccine has been cleared in the EU as a booster shot, although its role in the US could be impacted by new data on rare blood clots.
Three hurdles to allowing booster COVID-19 vaccinations for all adults in the US fell in swift succession on Friday, clearing the way for wider use of the Pfizer/BioNTech and Moderna shots.
The US is now pressing ahead with plans to extend its COVID-19 vaccination campaign to younger children aged five and over, prompting a debate about the policy in other countries.<
A US study has found that the immunity afforded by COVID-19 vaccines is much stronger than that stimulated by infection with SARS-CoV-2 in unvaccinated individuals.
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.